Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07729592) titled 'Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome' on July 22.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Sun Yat-sen University

Condition: Hepatocellular Carcinoma (HCC)

Intervention: Drug: Dapagliflozin Drug: Donafenib

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: July 2026

Target Sample Size: 44

To know more, visit https://clinicaltrials.gov/study/NCT07729592

Disclaimer: Curated by HT Syndication....